CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质母细胞瘤的嵌合抗原受体（CAR）T 细胞治疗
英文原题：Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
查看英文原题
Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤（GBM）是成人最常见且侵袭性最强的原发性脑肿瘤。当前主要治疗包括手术、化疗和放疗，但疗效有限。因此，研究者正在开发免疫治疗策略，利用机体天然防御机制对抗胶质瘤。嵌合抗原受体（CAR）T细胞过继细胞治疗使用患者自身T细胞，经基因改造后靶向肿瘤相关抗原：研究者从患者体内采集这些细胞，改造其识别肿瘤表达的特定蛋白，再回输患者体内以摧毁肿瘤细胞。本简要综述回顾CAR-T 细胞疗法的发展历史，介绍当前靶抗原，并总结该疗法在靶向GBM时面临的挑战。
展开英文摘要原文
Glioblastoma (GBM) are the most common and aggressive primary brain tumors in adults. Current mainstay treatments include surgery, chemotherapy, and radiation; however, these are ineffective. As a result, immunotherapy treatment strategies are being developed to harness the body's natural defense mechanisms against gliomas. Adoptive cell therapy with chimeric antigen receptor (CAR) T cells uses patients' own T cells that are genetically modified to target tumor-associated antigens.
These cells are harvested from patients, engineered to target specific proteins expressed by the tumor and re-injected into the patient with the goal of destroying tumor cells. In this mini review, we outline the history of CAR T cell therapy, describe current antigen targets, and review challenges this treatment faces specifically in targeting GBM.
论文信息
- 作者
- Feldman L、Brown C、Badie B
- 单位
- Division of Neurosurgery, City of Hope National Medical Center, Duarte, CA, 91010, USA. lfeldman@coh.org.United States
- 文献类型
- 非美国政府资助研究 · 综述
- 期刊
- Neuromolecular medicine2022 Mar
- 原文标识
- PubMed 34665390 · DOI 10.1007/s12017-021-08689-5
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →